Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflammation-targeted pharmacotherapy algorithm for COPD
ACTRN12613000046707Phase 4Completed
- Sponsor
- John Hunter Hospital
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of azithromycin, rosuvastatin and prednisolone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by John Hunter Hospital. Primary endpoint: Health-related quality of life responder rate. Started Aug 2013; status: completed.
02
Drugs
azithromycinrosuvastatinprednisolone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12613000046707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000046707.